Pfizer said it will seek regulatory approval for a Lyme disease vaccine candidate despite failing a late-stage trial. Pfizer said not enough people contracted Lyme disease to be confident in the ...

Pharmaceutical giant Pfizer PFE-1.10%decrease; red down pointing triangle and French vaccine maker Valneva VLA-4.41%decrease; red down pointing triangle reported positive topline results from their ...

Pfizer is behind Eli Lilly and Novo Nordisk in the GLP-1 race, but long-term investors shouldn't count the company out. GLP-1 drugs have seen strong consumer demand. Eli Lilly's industry-leading GLP-1 ...

Add Yahoo as a preferred source to see more of our stories on Google. A Pfizer logo is shown at a research facility in the La Jolla neighborhood of San Diego, California, U.S., September 30, 2025.

Pfizer has underperformed the market in each of the past three years. The stock is doing well of late as investors have been turning to safer investments amid uncertainty. Pfizer has been struggling ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: An illustration photo shows a dose of the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine from Skippack ...

Pfizer is working to get approval on a new vaccine that could protect people against Lyme disease, but the company could see pushback from the government following studies done on the vaccine. "What ...

Pfizer Inc. said its experimental Lyme disease vaccine was 73% effective against the tick-borne illness, though fewer-than-expected cases in a study made it hard to determine how well it works on a ...

Pfizer plans to shutter its South San Francisco research offices on April 30, ending its short tenure in the city. Pfizer planted its flag in South San Francisco in 2022 when it acquired Global Blood ...

Belgian court orders Poland, Romania to honour Pfizer contracts Poland, Romania argued pandemic changes justified refusal Court dismissed these claims Pfizer expects payment, Poland considers legal ...

Pfizer (PFE) is trading at $26.59 with shares up 9.31% year-to-date, while Guggenheim raised its price target to $36 with a Buy rating versus Wall Street’s cautious $28.14 consensus. Pfizer’s oncology ...